Expand / Collapse search
Watch TV
☰

Quotes displayed in real-time or delayed by at least 15 minutes. Market data provided by Factset. Powered and implemented by FactSet Digital Solutions.  Legal Statement.

This material may not be published, broadcast, rewritten, or redistributed. ©2025 FOX News Network, LLC. All rights reserved. FAQ - New Privacy Policy

labcorp holdings inc. - LH

LH

Close Chg Chg %
226.03 -5.56 -2.46%

Closed Market

220.47

-5.56 (2.46%)

Volume: 702.66K

Last Updated:

Apr 16, 2025, 3:59 PM EDT

Trade Now

Company Overview: labcorp holdings inc. - LH

LH Key Data

Open

$226.12

 Day Range

219.02 - 226.93

52 Week Range

191.97 - 258.59

 Market Cap

$18.91B

Shares Outstanding

83.67M

 Public Float

83.34M

Beta

0.99

 Rev. Per Employee

N/A

P/E Ratio

25.57

 EPS

$8.88

Yield

127.42%

 Dividend

$0.72

EX-DIVIDEND DATE

May 29, 2025

 SHORT INTEREST

N/A

AVERAGE VOLUME

827.62K

  

LH Performance

1 Week
 
 2.06%
 
1 Month
 
 -5.64%
 
3 Months
 
 -5.26%
 
1 Year
 
 12.18%
 
5 Years
 
 79.02%
 

LH Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 23
Full Ratings ➔

About labcorp holdings inc. - LH

Labcorp Holdings, Inc. engages in providing medical testing services. The company was founded on April 16, 2024 and is headquartered in Burlington, NC.

LH At a Glance

Labcorp Holdings, Inc.
358 South Main Street
Burlington, North Carolina 27215-5837
Phone 1-336-229-1127 Revenue 13.01B
Industry Medical/Nursing Services Net Income 746.00M
Sector Health Services 2024 Sales Growth 6.967%
Fiscal Year-end 12 / 2025 Employees 70,000
View SEC Filings

LH Valuation

P/E Current 25.055
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) 25.944
Price to Sales Ratio 1.488
Price to Book Ratio 2.375
Price to Cash Flow Ratio 12.205
Enterprise Value to EBITDA 12.328
Enterprise Value to Sales 1.931
Total Debt to Enterprise Value 0.289

LH Efficiency

Revenue/Employee 185,841.429
Income Per Employee 10,657.143
Receivables Turnover 6.204
Total Asset Turnover 0.741

LH Liquidity

Current Ratio 1.443
Quick Ratio 1.295
Cash Ratio 0.456

LH Profitability

Gross Margin 25.89
Operating Margin 8.748
Pretax Margin 7.376
Net Margin 5.735
Return on Assets 4.25
Return on Equity 9.368
Return on Total Capital 4.868
Return on Invested Capital 5.569

LH Capital Structure

Total Debt to Total Equity 90.321
Total Debt to Total Capital 47.457
Total Debt to Total Assets 39.571
Long-Term Debt to Equity 75.53
Long-Term Debt to Total Capital 39.685
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Labcorp Holdings Inc. - LH

Collapse All in section
All values USD millions. 2021 2022 2023 2024 5-year trend
Sales/Revenue
16.12B 14.88B 12.16B 13.01B
Sales Growth
+15.33% -7.72% -18.25% +6.97%
Cost of Goods Sold (COGS) incl D&A
10.87B 10.75B 9.02B 9.64B
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
940.00M 828.30M 580.90M 899.90M
Depreciation
570.40M 569.00M 361.10M 643.50M
Amortization of Intangibles
369.60M 259.30M 219.80M 256.40M
COGS Growth
+16.83% -1.06% -16.13% +6.93%
Gross Income
5.25B 4.13B 3.15B 3.37B
Gross Income Growth
+12.34% -21.48% -23.77% +7.09%
Gross Profit Margin
+32.60% +27.73% +25.86% +25.89%
2021 2022 2023 2024 5-year trend
SG&A Expense
1.89B 2.00B 2.02B 2.23B
Research & Development
- - - -
-
Other SG&A
1.89B 2.00B 2.02B 2.23B
SGA Growth
+10.91% +5.41% +1.24% +10.32%
Other Operating Expense
- - - -
-
Unusual Expense
101.10M 355.30M 398.10M 51.30M
EBIT after Unusual Expense
3.26B 1.77B 725.60M 1.09B
Non Operating Income/Expense
79.20M (11.00M) 42.90M 81.10M
Non-Operating Interest Income
10.20M 8.90M 28.80M 22.30M
Equity in Earnings of Affiliates
26.50M 5.40M (1.40M) (1.40M)
Interest Expense
212.10M 180.30M 199.60M 208.30M
Interest Expense Growth
+2.27% -14.99% +10.70% +4.36%
Gross Interest Expense
212.10M 180.30M 199.60M 208.30M
Interest Capitalized
- - - -
-
Pretax Income
3.13B 1.58B 568.90M 959.50M
Pretax Income Growth
+40.89% -49.38% -64.05% +68.66%
Pretax Margin
+19.39% +10.64% +4.68% +7.38%
Income Tax
747.10M 302.00M 188.50M 212.40M
Income Tax - Current - Domestic
717.40M 229.50M 222.00M 172.10M
Income Tax - Current - Foreign
107.70M 65.30M 44.60M 60.40M
Income Tax - Deferred - Domestic
(78.30M) 2.40M (94.70M) (17.40M)
Income Tax - Deferred - Foreign
300.00K 4.80M 16.60M (2.70M)
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
26.50M 5.40M (1.40M) (1.40M)
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
2.38B 1.28B 380.40M 747.10M
Minority Interest Expense
2.20M 1.50M 1.20M 1.10M
Net Income
2.38B 1.28B 379.20M 746.00M
Net Income Growth
+52.77% -46.20% -70.35% +96.73%
Net Margin Growth
+14.75% +8.60% +3.12% +5.73%
Extraordinaries & Discontinued Operations
- - - 38.80M
-
Discontinued Operations
- - - 38.80M
-
Net Income After Extraordinaries
2.38B 1.28B 418.00M 746.00M
Preferred Dividends
- - - -
-
Net Income Available to Common
2.38B 1.28B 418.00M 746.00M
EPS (Basic)
24.5843 14.0406 4.7991 8.8915
EPS (Basic) Growth
+53.72% -42.89% -65.82% +85.27%
Basic Shares Outstanding
96.70M 91.10M 87.10M 83.90M
EPS (Diluted)
24.3826 13.964 4.7717 8.8389
EPS (Diluted) Growth
+53.56% -42.73% -65.83% +85.24%
Diluted Shares Outstanding
97.50M 91.60M 87.60M 84.40M
EBITDA
4.30B 2.96B 1.70B 2.04B
EBITDA Growth
+13.33% -31.23% -42.36% +19.55%
EBITDA Margin
+26.68% +19.88% +14.02% +15.67%

Snapshot

Average Recommendation OVERWEIGHT Average Target Price 272.294
Number of Ratings 23 Current Quarters Estimate 4.173
FY Report Date 06 / 2025 Current Year's Estimate 16.058
Last Quarter’s Earnings 3.757 Median PE on CY Estimate N/A
Year Ago Earnings 14.57 Next Fiscal Year Estimate 17.665
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates 16 16 19 19
Mean Estimate 4.17 4.09 16.06 17.66
High Estimates 4.51 4.26 16.62 18.34
Low Estimate 3.95 3.96 15.86 17.18
Coefficient of Variance 3.26 2.01 1.02 2.00

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 15 14 12
OVERWEIGHT 3 2 2
HOLD 5 6 7
UNDERWEIGHT 0 0 0
SELL 0 0 0
MEAN Overweight Overweight Overweight

Insider Actions for Labcorp Holdings Inc. - LH

Date Name Shares Transaction Value
Apr 4, 2025 Megan D. Bailey EVP, Pres, Central Labs & Intl 4,813 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Apr 4, 2025 Megan D. Bailey EVP, Pres, Central Labs & Intl 3,173 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Apr 4, 2025 Megan D. Bailey EVP, Pres, Central Labs & Intl 2,969 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Apr 4, 2025 Megan D. Bailey EVP, Pres, Central Labs & Intl 3,471 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Apr 4, 2025 Megan D. Bailey EVP, Pres, Central Labs & Intl 3,267 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $232.65 per share 760,067.55
Apr 4, 2025 Megan D. Bailey EVP, Pres, Central Labs & Intl 3,403 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $232.65 per share 791,707.95
Apr 1, 2025 Mark S. Schroeder EVP, Pres Diagnostics & COO 9,800 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Apr 1, 2025 Adam H. Schechter President & CEO; Director 118,651 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Apr 1, 2025 Adam H. Schechter President & CEO; Director 105,067 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $231.67 per share 24,340,871.89
Apr 1, 2025 Peter J. Wilkinson SVP, Chief Accounting Officer 3,242 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Apr 1, 2025 Peter J. Wilkinson SVP, Chief Accounting Officer 2,883 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $231.67 per share 667,904.61
Apr 1, 2025 Akinbolade Oyegunwa EVP, CIO & CTO 3,464 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $231.67 per share 802,504.88
Apr 1, 2025 Sandra Danett van der Vaart EVP, Chief Legal Officer 5,496 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Apr 1, 2025 Sandra Danett van der Vaart EVP, Chief Legal Officer 4,144 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $231.67 per share 960,040.48
Apr 1, 2025 Mark S. Schroeder EVP, Pres Diagnostics & COO 7,595 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $231.67 per share 1,759,533.65
Apr 1, 2025 Brian J. Caveney EVP, Pres of ED, CMO & CSO 34,176 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Apr 1, 2025 Amy B. Summy EVP, Chief Marketing Officer 6,060 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $231.67 per share 1,403,920.20
Apr 1, 2025 Glenn Andrew Eisenberg Executive Vice President 37,920 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $231.67 per share 8,784,926.40
Apr 1, 2025 Amy B. Summy EVP, Chief Marketing Officer 6,622 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Apr 1, 2025 Mark S. Schroeder EVP, Pres Diagnostics & COO 4,960 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $231.67 per share 1,149,083.20

Labcorp Holdings Inc. in the News